<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194439</url>
  </required_header>
  <id_info>
    <org_study_id>1405976232</org_study_id>
    <secondary_id>1R01HD074587-01</secondary_id>
    <nct_id>NCT02194439</nct_id>
  </id_info>
  <brief_title>Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease</brief_title>
  <official_title>Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to collect longitudinal biological samples from patients after&#xD;
      hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers&#xD;
      to validate biomarkers of both acute and chronic GVHD as well as for use in future&#xD;
      unspecified research. The centers include Dana-Farber Cancer Institute and Boston's&#xD;
      Children's Hospital, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred Hutchinson&#xD;
      Cancer Research Center, Texas Children's Hospital, Children's National Medical Center, and&#xD;
      Indiana University Simon Cancer Center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent is signed, this study will involve 1) collection of basic HCT data and&#xD;
      clinical data available in the medical record and 2) providing blood (and saliva in&#xD;
      occasional cases) samples for processing, storage, DNA extraction, and analysis (including a&#xD;
      seven biomarker protein panel as well as future unspecified research purposes).&#xD;
&#xD;
      Pediatric and adult patients will be included (all adult patients will be from the Fred&#xD;
      Hutchinson Cancer Research Center, the Johns Hopkins Sidney Kimmel Comprehensive Cancer&#xD;
      Center, and the Indiana University Simon Cancer Center).&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      1. To confirm that ST2 alone or the seven-biomarker panel measured at initiation of GVHD&#xD;
      therapy predict a) D180 post-therapy non-relapse mortality; b) D28 post-therapy non-response,&#xD;
      and c) GVHD grade 1-4 onset D180 post-therapy non-relapse mortality.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        1. To demonstrate that ST2 alone or the seven-biomarker panel measured at day 14 or day 21&#xD;
           post-HCT (or a combination of these time points) predicts D180 post-HCT non-relapse&#xD;
           mortality.&#xD;
&#xD;
        2. To demonstrate that ST2 alone or the seven-biomarker panel measured at initiation of&#xD;
           GVHD symptoms/therapy diagnose acute GVHD as compared to other complications presenting&#xD;
           with similar symptoms (drug rash, CMV, Clostridium enteritis).&#xD;
&#xD;
        3. To demonstrate that ST2 alone or the seven-biomarker panel measured at initiation of&#xD;
           GVHD symptoms/therapy diagnose the severity of acute GVHD at onset and maximum.&#xD;
&#xD;
        4. To develop a repository of biospecimens linked to clinical data for future unspecified&#xD;
           research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT</measure>
    <time_frame>1 year</time_frame>
    <description>To measure stimulation-2 (ST2) pre-HCT by number of participants at 12 months post-HCT for non-relapse mortality according to ST2 values and age less than or equal to 10 and greater than 10 using landmark analyses.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">415</enrollment>
  <condition>Graft-Versus-Host Disease</condition>
  <arm_group>
    <arm_group_label>hematopoietic stem cell transplant</arm_group_label>
    <description>procedure</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, Plasma, Peripheral Blood Mononuclear Cells (PBMC), Saliva, Bronchoalveolar&#xD;
      lavage (BAL)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients receiving an allogeneic hematopoietic stem cell transplant, cord blood transplant,&#xD;
        bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion (DLI), or donor&#xD;
        cellular infusion (DCI) from Dana-Farber Cancer Institute and Boston Children's Hospital,&#xD;
        Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred Hutchinson Cancer Research&#xD;
        Center, Texas Children's Hospital, Children's National Medical Center, and Indiana&#xD;
        University Simon Cancer Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: - All patients receiving an allogeneic hematopoietic stem cell&#xD;
        transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor&#xD;
        lymphocyte infusion (DLI), or donor cellular infusion (DCI) can be included.&#xD;
&#xD;
        Exclusion Criteria: - patients not receiving an allogeneic hematopoietic stem cell&#xD;
        transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor&#xD;
        lymphocyte infusion (DLI), or donor cellular infusion (DCI) will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Paczesny, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Unversity Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <results_first_submitted>February 6, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Sophie Paczesny</investigator_full_name>
    <investigator_title>Professor of Pediatrics and Immunology</investigator_title>
  </responsible_party>
  <keyword>Acute Graft Versus Host Disease</keyword>
  <keyword>Affect</keyword>
  <keyword>Anti-inflammatory</keyword>
  <keyword>Anti-inflammatory Agents</keyword>
  <keyword>Antigen-Presenting Cells</keyword>
  <keyword>Alloantigen</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Allograft rejection</keyword>
  <keyword>Allograft Tolerance</keyword>
  <keyword>Antigens</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Biospecimen Repository</keyword>
  <keyword>BMT</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Cell Transplantation</keyword>
  <keyword>Cells</keyword>
  <keyword>Clonal Expansion</keyword>
  <keyword>Complex</keyword>
  <keyword>Cytokine</keyword>
  <keyword>Data</keyword>
  <keyword>Development</keyword>
  <keyword>Environment</keyword>
  <keyword>Failure (biologic function)</keyword>
  <keyword>Genomics</keyword>
  <keyword>Graft-vs-Host Disease</keyword>
  <keyword>Graft-vs-Leukemia</keyword>
  <keyword>GVHD</keyword>
  <keyword>GVL</keyword>
  <keyword>Hematopoietic</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>HCT</keyword>
  <keyword>HSCT</keyword>
  <keyword>IL-33 Receptor</keyword>
  <keyword>Immune Reconstitution</keyword>
  <keyword>Immune Response</keyword>
  <keyword>Inflammatory</keyword>
  <keyword>Modeling</keyword>
  <keyword>Novel</keyword>
  <keyword>Novel therapeutics</keyword>
  <keyword>Outcome</keyword>
  <keyword>Pathway interactions</keyword>
  <keyword>Peptides</keyword>
  <keyword>Prevent</keyword>
  <keyword>Process</keyword>
  <keyword>Production</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Regulatory T-Lymphocyte</keyword>
  <keyword>Response</keyword>
  <keyword>Role</keyword>
  <keyword>Signal</keyword>
  <keyword>ST2</keyword>
  <keyword>Transduction</keyword>
  <keyword>T-cell response</keyword>
  <keyword>T-cell Activation</keyword>
  <keyword>T-Lymphocytes</keyword>
  <keyword>Tissues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02194439/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02194439/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>4 plasma biomarkers were assessed pre-HCT and at days +7, +14 and +21 post-HCT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="415"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="415"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who performed biomarker collection.</population>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>4 plasma biomarkers were assessed pre-HCT and at days +7, +14 and +21 post-HCT.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="415"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age &lt;10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &gt;10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT</title>
        <description>To measure stimulation-2 (ST2) pre-HCT by number of participants at 12 months post-HCT for non-relapse mortality according to ST2 values and age less than or equal to 10 and greater than 10 using landmark analyses.</description>
        <time_frame>1 year</time_frame>
        <population>Participants who had all four biomarkers and four timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplant</title>
            <description>4 plasma biomarkers were assessed pre-HCT and at days +7, +14 and +21 post-HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT</title>
          <description>To measure stimulation-2 (ST2) pre-HCT by number of participants at 12 months post-HCT for non-relapse mortality according to ST2 values and age less than or equal to 10 and greater than 10 using landmark analyses.</description>
          <population>Participants who had all four biomarkers and four timepoints.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age &lt;10 high Pre-HCT ST2 &gt;26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &lt;10 low pre-HCT ST2 &lt;26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &gt;10 high Pre-HCT ST2 &gt;26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &gt;10 low Pre-HCT ST2 &lt;26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplant</title>
          <description>4 plasma biomarkers were assessed pre-HCT and at days +7, +14 and +21 post-HCT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="415"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="415"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sophie Paczesny</name_or_title>
      <organization>IndianaU</organization>
      <phone>317-278-5487</phone>
      <email>sophpacz@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

